Materials And Products Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Rivaroxaban (Atc: B01af01 - with a Potency of 2.5 Mg Per Divided Oral Dosage Form).

Drug Discount Agreements for Various Active Ingredients as Part of an Open House Procedure

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Clobetasol (Atc Code: D07ad01).

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Lisdexamfetamine (Atc Code According to Who: N06ba12)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Tolvaptan (Atc Code: C03xa01)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Tolvaptan (Atc Code: G04bx21)

Open Framework Agreement on Drug Discounts in Accordance with Section 130A Paragraph 8 Sentence 1 Sgb V with the Possibility of Joining at any Time, So-Called Approval Model 2024-07

Medicines with the Active Ingredient Alitretinoin (Atc: D11ah04)

Medicines with the Active Ingredient Pomalidomide (Atc: L04ax06)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Latanoprost/Timolol (Official Atc Code: S01ed61)